Evan Lockwood Rachlin
Evan Lockwood Rachlin has made 1 open-market purchase worth $11.5M since Oct 19, 2026, in 1 company. The latest: $11.5M of IAM, filed Oct 19, 2026, scored 46 out of 100.
Director, Iambic Therapeutics, Inc.
Follow Evan Lockwood Rachlin, freeOpen the live feed
A free account gets an alert the minute a new buy or sale is filed.
Purchases
| Filed | Stock | Stake | Score | Bought | 1 week | 1 month |
|---|---|---|---|---|---|---|
| Oct 19 Form 4 (opens sec.gov) |
IAMIambic Therapeutics, Inc. · DirectorDirector | +38% stake | 46 | $11.5M 718,750 at $16.00 |
−12.6% | waiting |
Track record (hypothetical): a week after the filing, these buys averaged −12.6% (0% up, 1 measured).
Questions
What stock has Evan Lockwood Rachlin bought?
IAM (Iambic Therapeutics, Inc.), all on the open market and reported on SEC Form 4.
When did Evan Lockwood Rachlin last buy?
Oct 19, 2026: 718,750 shares of IAM at $16.00, $11.5M in all (Form 4 (opens sec.gov)).
Has Evan Lockwood Rachlin filed a notice of a planned sale?
Not in the filings on record. A Form 144 is the notice an insider must file before selling restricted or control shares, and it lands on EDGAR before the sale is reported.
Is Evan Lockwood Rachlin a routine or an opportunistic buyer?
There isn't enough history to say yet.
Data as of Oct 19, 2026, from SEC EDGAR Form 4 filings: open-market purchases (code P) of $25,000 or more, and open-market sales. Every row links to its filing. Scores summarise what a filing says (how the score works); outcomes are hypothetical, from the first close after the filing, and past results don't predict future ones. Disclaimer